Sernova Corp. | Balance Sheet

Fiscal year is November-October. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
4,975.90
3,416.70
2,881.00
5,899.50
3,631.90
2,743.30
Total Accounts Receivable
51.10
114.70
219.30
231.40
641.40
471.60
Other Current Assets
131.30
41.80
23.80
67.80
39.80
101.30
Total Current Assets
5,158.30
3,573.20
3,124.10
6,198.60
4,313.00
3,316.20
Net Property, Plant & Equipment
19.70
14.80
29.20
26.70
238.50
289
Intangible Assets
1,065.80
433.00
-
-
-
-
Total Assets
6,243.80
4,021.10
3,153.30
6,225.20
4,551.50
3,605.20
Accounts Payable
111.00
122.40
-
-
-
Other Current Liabilities
114.20
117.70
199.90
846.30
901.10
Total Current Liabilities
225.10
240.10
199.90
846.30
901.10
Total Liabilities
225.10
240.10
199.90
846.30
901.10
Common Equity (Total)
6,018.60
3,781.00
2,953.40
5,379.00
3,650.50
Total Shareholders' Equity
6,018.60
3,781.00
2,953.40
5,379.00
3,650.50
Total Equity
6,018.60
3,781.00
2,953.40
5,379.00
3,650.50
Liabilities & Shareholders' Equity
6,243.80
4,021.10
3,153.30
6,225.20
4,551.50

About Sernova

View Profile
Address
700 Collip Circle
London Ontario N6G 4X8
Canada
Employees -
Website http://www.sernova.com
Updated 07/08/2019
Sernova Corp. is a clinical stage regenerative medicine company. It engages in the business of developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins and hormones missing within the body. It also focuses in the manufacture and clinical evaluation of the cell pouch for insulin-dependent diabetes.